RxDoctor Payments Data

Sana Chaudhary, MD

Rheumatology · Danbury, CTNPI 1831548684

Payments from drug & device makers

What this record shows

Almost everything reported here is food and beverage — 100.0% of the total across 52 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. 12 manufacturers reported payments, led by AbbVie at 40.5% of the total. Reporting peaked in 2022 at $558 and has fallen 61.0% since, to $217 in 2025. That places this record below the midpoint for rheumatology clinicians in CT, where the typical reported total is $1,253.

$1,361in general payments, 2019–2025

Across 52 payments — averaging $26.17 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$551
  • UCB, Inc.$181
  • AstraZeneca$181
  • Novartis$153
  • Johnson & Johnson$119
  • GSK$49
  • plus $127 from 6 others

What the payments were for

  • Food & beverage$1,361100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$1,361 in reported general payments places this provider in the 50th percentile of 118 rheumatology providers in Connecticut.

See all rheumatology providers in Connecticut

Medicare billing

Part B allowed, 2024
$482,210
Medicare patients
492
Services billed
47,536

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Humira(Cf) PenAdalimumab63$479,499
Enbrel SureclickEtanercept18$151,843
Xeljanz XrTofacitinib Citrate15$98,217
Enbrel MiniEtanercept11$95,303
HumiraAdalimumab11$74,267
RasuvoMethotrexate/Pf46$26,237
Teriparatide13$23,514
Hydroxychloroquine Sulfate337$12,371
MethotrexateMethotrexate Sodium297$6,091
Prednisone372$2,588
Colchicine32$2,528
Gabapentin87$1,843
Celecoxib55$1,428
Leflunomide31$1,285
Alendronate Sodium150$1,124

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AbbVieHumira$551$74,26711 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 50th percentile of 118 rheumatology providers in Connecticut.

Other rheumatology in Danbury

See the full list for Connecticut

Where these figures come from

Is this you, or does something look wrong? →